Last reviewed · How we verify

NCT04640337

Influence of Placebo on Intratissue Percutaneous Electrolysis in Patellar Tendinopathy

Status unknown NA Last updated 9 May 2023
What this trial tests

NA trial testing IPE applied, participants believe they are receiving IPE in Patellar Tendinopathy in 60 participants. Status unknown.

Timeline
16 October 2020
Primary endpoint
20 December 2023
20 March 2024

Quick facts

Lead sponsorUniversity of Valencia
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment60
Start date16 October 2020
Primary completion20 December 2023
Estimated completion20 March 2024
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

University of Valencia

Who can join

18 and older, any sex, with Patellar Tendinopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim of this study is to verify the influence of placebo on the effectiveness of Intratissue Percutaneous Electrolysis (IPE) in patients suffering from with chronic patellar tendinopathy (PT). The secondary aim is to investigate the possible influence of the IPE on pain perception and conditioned pain modulation (CPM) in patients with chronic PT.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Patellar Tendinopathy

Currently open trials in the same condition.

Other University of Valencia trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04640337.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing